Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: A post-hoc analysis of a prospective observational study

BMC Psychiatry

Volumn 12, Issue , 2012, Pages

  Haynes, Virginia S ^a   Zhu, Baojin ^a   Stauffer, Virginia L ^a   Kinon, Bruce J ^a   Stensland, Michael D ^b   Xu, Lei ^a   Ascher Svanum, Haya ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Agile Outcomes Research Inc   (United States)

Author keywords

Health care costs; Observational studies; Prospective studies; Schizophrenia; Symptom remission; Treatment outcome

Indexed keywords

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; EMERGENCY HEALTH SERVICE; EMPLOYMENT; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING SCALE; HEALTH CARE COST; HEALTH CARE PLANNING; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; MENTAL COMPONENT SUMMARY SCORE; MENTAL HEALTH SERVICE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; POST HOC ANALYSIS; QUALITY OF LIFE; QUALITY OF LIFE SCALE; REMISSION; SCHIZOPHRENIA; SHORT FORM 12; SUBSTANCE ABUSE; SYMPTOM; VICTIM; VIOLENCE; CRIME VICTIM; GLOBAL ASSESSMENT OF FUNCTIONING; MEDICAL RECORD; PROSPECTIVE STUDY; SUBSTANCE USE; UNITED STATES;

ADULT; FEMALE; HUMANS; MALE; MENTAL HEALTH SERVICES; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; REMISSION INDUCTION; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84870366856     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-12-222     Document Type: Article

References (41)

1. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005, 66:1122-1129. 10.4088/JCP.v66n0906, 16187769.
2. Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, Conley RR. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010, 10:2. 10.1186/1471-244X-10-2, 2817695, 20059765.
3. Jobe TH, Harrow M. Long-term outcome of patients with schizophrenia: a review. Can J Psychiatry 2005, 50:892-900.
4. Harrow M, Jobe TH. How frequent is chronic multiyear delusional activity and recovery in schizophrenia: a 20-year multi-follow-up. Schizophr Bull 2010, 36:192-204. 10.1093/schbul/sbn074, 2800138, 18617485.
5. Harrow M, Jobe TH. Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollow-up study. J Nerv Ment Dis 2007, 195:406-414.
6. Menezes NM, Arenovich T, Zipursky RB. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med 2006, 36:1349-1362. 10.1017/S0033291706007951, 16756689.
7. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005, 162:441-449. 10.1176/appi.ajp.162.3.441, 15741458.
8. Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D. Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later. Dialogues Clin Neurosci 2010, 12:393-407. 3181974, 20954433.
9. Addington J, Addington D. Symptom remission in first episode patients. Schizophr Res 2008, 106:281-285. 10.1016/j.schres.2008.09.014, 18926666.
10. De Hert M, van Winkel R, Wampers M, Kane J, van Os J, Peuskens J. Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophr Res 2007, 92:68-73. 10.1016/j.schres.2007.01.010, 17336500.
11. Dunayevich E, Sethuraman G, Enerson M, Taylor CC, Lin D. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes. Schizophr Res 2006, 86:300-308. 10.1016/j.schres.2006.06.002, 16860974.
12. Emsley R, Oosthuizen PP, Kidd M, Koen L, Niehaus DJH, Turner HJ. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J Clin Psychiatry 2006, 67:1707-1712. 10.4088/JCP.v67n1106, 17196049.
13. Emsley R, Rabinowitz J, Medori R. Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates. Schizophr Res 2007, 89:129-139. 10.1016/j.schres.2006.09.013, 17095194.
14. Helldin L, Kane JM, Hjärthag F, Norlander T. The importance of cross-sectional remission in schizophrenia for long-term outcome: a clinical prospective study. Schizophr Res 2009, 115:67-73. 10.1016/j.schres.2009.07.004, 19666215.
15. Kane JM, Crandall DT, Marcus RN, Eudicone J, Pikalov A, Carson WH, Swyzen W. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr Res 2007, 95:143-150. 10.1016/j.schres.2007.05.009, 17644313.
16. Kelly DL, Weiner E, Ball MP, McMahon RP, Carpenter WT, Buchanan RW. Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study. J Psychopharmacol (Oxford) 2009, 23:436-441.
17. Opler MGA, Yang LH, Caleo S, Alberti P. Statistical validation of the criteria for symptom remission in schizophrenia: preliminary findings. BMC Psychiatry 2007, 7:35. 10.1186/1471-244X-7-35, 1949820, 17650312.
18. Wunderink L, Nienhuis FJ, Sytema S, Wiersma D. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophr Bull 2007, 33:792-796. 10.1093/schbul/sbl015, 2526146, 16894026.
19. Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull 2008, 34:1163-1171. 10.1093/schbul/sbm134, 2632496, 18156640.
20. Bodén R, Sundström J, Lindström E, Lindström L. Association between symptomatic remission and functional outcome in first-episode schizophrenia. Schizophr Res 2009, 107:232-237. 10.1016/j.schres.2008.10.004, 18957275.
21. Brissos S, Dias VV, Balanzá-Martinez V, Carita AI, Figueira ML. Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance. Schizophr Res 2011, 129:133-136. 10.1016/j.schres.2011.04.001, 21514793.
22. Ciudad A, Alvarez E, Bobes J, San L, Polavieja P, Gilaberte I. Remission in schizophrenia: results from a 1-year follow-up observational study. Schizophr Res 2009, 108:214-222. 10.1016/j.schres.2008.12.004, 19168329.
23. Eberhard J, Levander S, Lindström E. Remission in schizophrenia: analysis in a naturalistic setting. Compr Psychiatry 2009, 50:200-208. 10.1016/j.comppsych.2008.08.010, 19374962.
24. Lehman AF, Fischer EP, Postrado L, Delahanty J, Johnstone BM, Russo PA, Crown WH. The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): an instrument to assess outcomes of schizophrenia care. Schizophr Bull 2003, 29:247-256. 10.1093/oxfordjournals.schbul.a007001, 14552500.
25. Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006, 6:8. 10.1186/1471-244X-6-8, 1402287, 16504026.
26. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders DSM-IV 1994, Washington, DC: American Psychiatric Association, 4, American Psychiatric Association.
27. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr Bull 1987, 13:261-276. 10.1093/schbul/13.2.261, 3616518.
28. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984, 10:388-398. 10.1093/schbul/10.3.388, 6474101.
29. Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996, 34:220-233. 10.1097/00005650-199603000-00003, 8628042.
30. Lasser RA, Bossie CA, Gharabawi GM, Kane JM. Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection. Schizophr Res 2005, 77:215-227. 10.1016/j.schres.2005.03.006, 15908183.
31. Robinson DG, Woerner MG, Alvir JMJ, Bilder RM, Hinrichsen GA, Lieberman JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 2002, 57:209-219. 10.1016/S0920-9964(01)00312-7, 12223252.
32. Lambert M, Schimmelmann BG, Naber D, Schacht A, Karow A, Wagner T, Czekalla J. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry 2006, 67:1690-1697. 10.4088/JCP.v67n1104, 17196047.
33. Bellack AS. Scientific and consumer models of recovery in schizophrenia: concordance, contrasts, and implications. Schizophr Bull 2006, 32:432-442. 2632241, 16461575.
34. Barber ME. Recovery as the new medical model for psychiatry. Psychiatr Serv 2012, 63:277-279. 10.1176/appi.ps.201100248, 22388534.
35. Silverstein SM, Bellack AS. A scientific agenda for the concept of recovery as it applies to schizophrenia. Clin Psychol Rev 2008, 28:1108-1124. 10.1016/j.cpr.2008.03.004, 18420322.
36. Lysaker PH, Erikson M, Macapagal KR, Tunze C, Gilmore E, Ringer JM. Development of personal narratives as a mediator of the impact of deficits in social cognition and social withdrawal on negative symptoms in schizophrenia. J Nerv Ment Dis 2012, 200:290-295. 10.1097/NMD.0b013e31824cb0f4, 22456581.
37. Lysaker PH, Roe D, Ringer J, Gilmore EM, Yanos PT. Change in self-stigma among persons with schizophrenia enrolled in rehabilitation: associations with self-esteem and positive and emotional discomfort symptoms. Psychol Serv 2012, 9:240-247.
38. Baillargeon J, Binswanger IA, Penn JV, Williams BA, Murray OJ. Psychiatric disorders and repeat incarcerations: the revolving prison door. Am J Psychiatry 2009, 166:103-109. 10.1176/appi.ajp.2008.08030416, 19047321.
39. Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study. Schizophr Res 2011, 133:42-46. 10.1016/j.schres.2011.09.018, 22000938.
40. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009, 35:443-457. 10.1093/schbul/sbn018, 2659301, 18417466.
41. Lysaker PH, Leonhardt BL. Agency: its nature and role in recovery from severe mental illness. World Psychiatry 2012, 11:165-166. 3449358, 23024671.